Zentalis Pharmaceuticals Inc ( (ZNTL) ) has released its Q1 earnings. Here is a breakdown of the information Zentalis Pharmaceuticals Inc presented to its investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Zentalis Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing azenosertib, a WEE1 inhibitor, for treating Cyclin E1-positive platinum-resistant ovarian cancer. In its latest earnings report for the quarter ending March 31, 2025, Zentalis Pharmaceuticals reported a net loss of $48.3 million, compared to a net income of $10 million in the same period last year. The company experienced a significant decrease in license revenue, which was $40.6 million in the previous year, and a reduction in research and development expenses. Key financial metrics include a decrease in cash and cash equivalents to $41.9 million and a reduction in marketable securities to $278.4 million. The company also reported restructuring expenses of $7.8 million. Looking ahead, Zentalis Pharmaceuticals remains focused on advancing its clinical trials for azenosertib and exploring strategic opportunities to maximize the value of its pipeline.